Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Report reveals long AE disclosure gap

This article was originally published in The Tan Sheet

Executive Summary

Abbott Medical Optics waited 15 months to disclose to FDA complaints of serious corneal infections by users of its Complete MoisturePlus contact lens solution, says Washington-based law firm Schmidt & Clark in a June 22 release. The firm says an FDA report obtained under the Freedom of Information Act links the eye infection Acanthamoeba Keratitis to the Irvine, Calif.-based company's contact lens solution. AMO recalled Complete MoisturePlus in May 2007 (1"The Tan Sheet" June 4, 2007)

You may also be interested in...



AMO recalls Complete MoisturePlus

Advanced Medical Optics recalls the multipurpose contact lens solution after the Centers for Disease Control and Prevention reports a potential link between the product and Acanthamoeba keratitis, a rare eye infection, the Santa Ana, Calif.-based firm announces May 25. AMO says it voluntary initiated a worldwide recall out of "an abundance of caution" in response to reports 46 people had developed AK, 21 of whom used Complete MositurePlus the month prior to symptom onset. AMO adds the current recall is unrelated to reports of the fungal infection Fusarium keratitis that led to Bausch & Lomb's worldwide recall of its ReNu with MoistureLoc contact lens solution in 2006 1("The Tan Sheet," April 17, 2006, p. 5)...

COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs

The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.

COVID-19: FDA Schedules 4 More Virtual Town Halls Through October

The US agency has announced another month of webinars aimed at labs and manufacturers that are developing – or have developed – diagnostic tests for the novel coronavirus.

Topics

UsernamePublicRestriction

Register

LL079488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel